文献速递血栓与止血

核苷类逆转录酶抑制增强COVID-19患者血小板生成与巨核细胞成熟

Nucleoside reverse transcriptase inhibition enhances platelet production and megakaryocyte maturation in patients with COVID-19.
PubMed 文献 · Br J Haematol · 2025-02-10

该研究先回顾性分析177例高危COVID-19住院患者,其中64例接受阿兹夫定、12例接受奈玛特韦-利托那韦、101例未接受抗病毒治疗,发现接受阿兹夫定或奈玛特韦-利托那韦者血小板计数增量显著高于未治疗者(p=0.001),且阿兹夫定组升高幅度显著大于对照组(p<0.001)和奈玛特韦-利托那韦组(p=0.042)。体外实验显示阿兹夫定促进MEG-01细胞多倍体化和血小板生成,RNA测序显示VWF、TUBB1、GP1BA及PI3K/AKT、JAK/STAT通路相关基因上调。

要点

  • 高危COVID-19住院患者中,阿兹夫定或奈玛特韦-利托那韦组血小板计数增量显著高于未抗病毒治疗组(p=0.001)。
  • 阿兹夫定组血小板升高幅度显著大于对照组(p<0.001)和奈玛特韦-利托那韦组(p=0.042)。
  • 阿兹夫定在体外促进MEG-01细胞多倍体化和血小板生成,并上调VWF、TUBB1、GP1BA及PI3K/AKT、JAK/STAT通路相关基因。

核心结论

  • 核苷类逆转录酶抑制可能增强COVID-19患者血小板生成和巨核细胞成熟,提示血小板减少症的新治疗选择。

研究设计与样本

  • 回顾性研究纳入177例高危COVID-19住院患者,其中64例接受阿兹夫定、12例接受奈玛特韦-利托那韦、101例未接受抗病毒治疗;另进行体外实验和RNA测序。

主要发现

  • 与未接受抗病毒治疗者相比,接受阿兹夫定或奈玛特韦-利托那韦者的血小板计数增量显著更高(p=0.001)。
  • 阿兹夫定组血小板计数升高幅度显著大于对照组(p<0.001)和奈玛特韦-利托那韦组(p=0.042)。
  • 阿兹夫定促进MEG-01细胞系多倍体化和血小板生成,在有无SARS-CoV-2刺突-膜重组融合蛋白存在时均可显著触发巨核细胞血小板释放。
  • RNA测序显示阿兹夫定处理的MEG-01细胞中VWF、TUBB1和GP1BA明显增加,且PI3K/AKT和JAK/STAT信号通路相关基因上调。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronavirus disease 2019 (COVID-19) is a systemic infection frequently involving the haematopoietic system. Thrombocytopenia is associated with increased risks of severe disease progression and mortality. Antiviral agents have shown much promise in decreasing viral load and shortening the time to the resolution of symptoms. However, their effect on platelet counts in patients with COVID-19 remains unexplored. Therefore, we first performed a retrospective study to evaluate the variation in platelet mass of hospitalized patients with high-risk COVID-19 who were given either SARS-CoV-2 main protease inhibitor, nucleoside reverse transcriptase inhibitor or no antiviral agents. A total of 177 patients were included, among which 64 received azvudine, 12 received nirmatrelvir-ritonavir and 101 patients received none. Compared to those without antiviral treatment, significantly higher platelet counts' increments were observed in patients receiving azvudine or nirmatrelvir-ritonavir (p = 0.001). Of note, this elevation was significantly more profound in the azvudine group than that in the control group (p < 0.001) or the nirmatrelvir-ritonavir group (p = 0.042). Subsequently, in vitro experiments were conducted to investigate the mechanism of platelet elevation underlying the activity of azvudine. Results showed that azvudine promoted the polyploidization and platelet production of the MEG-01 cell line. Although azvudine had minimal effect on megakaryopoiesis, it could significantly trigger platelet release of megakaryocytes in the presence of SARS-CoV-2 spike-membrane recombinant fusion protein or not. Finally, RNA-sequencing demonstrated that azvudine-treated MEG-01 exhibited a marked increase in VWF, TUBB1 and GP1BA, and upregulated genes associated with the PI3K/AKT and JAK/STAT signalling pathways. In conclusion, our findings indicated that nucleoside reverse transcriptase inhibition potentially enhances platelet production and megakaryocyte maturation in patients with COVID-19, suggesting a new therapeutic option for thrombocytopenia.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Li Y, Wang J, Huang B, et al. Nucleoside reverse transcriptase inhibition enhances platelet production and megakaryocyte maturation in patients with COVID-19. Br J Haematol. 2025. PMID: 39930897. doi:10.1111/bjh.20006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。